Nick Dragojlovic
Nick Dragojlovic is a health services researcher at the University of British Columbia's Faculty of Pharmaceutical Sciences. He has previously held postdoctoral fellowships at the University of Calgary and at UBC, and has received funding from the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research. He holds a BA from Yale University and an MA and PhD from UBC. Nick is particularly interested in the use of alternative finance mechanisms to support scientific research, and covers the topic on his blog: Funded Science
Posts by: Nick
. The U.S. Food and Drug Administration’s (FDA) ongoing efforts to assert its authority to regulate U.S.-based companies that offer unlicensed stem cell therapies (Regenerative Sciences or Celltex, for example) has prompted a mixed response from the regenerative medicine community. On the one hand, getting an unlicensed treatment has many potential downsides, so the FDA’s […]
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is consistent with existing statutes, such as the Dickey-Wicker Amendment. The principal implication of this […]
“Stem Cells Make Aging Mice Young Again” – ABC News “’Factor X’ — Have we finally found the fountain of youth?” – Fox News “Stem cells, the secret to eternal youth?” – Euronews.com Headlines like these are all too common and underscore how the news media’s coverage of regenerative medicine tends to focus on the […]
If you’ve been feeling like you can’t open a web browser these days without finding a story about induced pluripotent stem cells (iPSCs), you’re not alone. Unlike embryonic stem cells, iPSCs are created by directly reprogramming adult cells taken from donors or patients, and they’ve been all over the news. Most notably, Sir John B. […]
State politics and the stem cell policy environment in the United States
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is consistent with existing statutes, such as the Dickey-Wicker Amendment. The principal implication of this […]